• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, June 25, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

TGA cautions drug suppliers over eye health references

by Myles Hume
June 3, 2020
in Local, News, Therapeutics
Reading Time: 3 mins read
A A
The group originally assigned lutein/zeaxanthin had an additional 20% reduced risk of progression to late AMD.

The group originally assigned lutein/zeaxanthin had an additional 20% reduced risk of progression to late AMD.

Share on FacebookShare on Twitter

A review of 13 medicines mentioning macular degeneration in Australia found all had inappropriately referenced the disease, prompting the health regulator to urge suppliers of listed medicines with eye health indications to reassess their compliance.

Last week, the Therapeutic Goods Administration (TGA) announced the findings from its targeted compliance review, which began in 2017, after consumers and industry figures signalled that some listed medicines indicated for eye health did not meet regulatory requirements.

This, according to the authority, was due to inappropriately referencing of macular degeneration and there being insufficient scientific evidence to support the indications. Macular degeneration is a ‘restricted representation’, a reference to a serious form of a disease. As such, reference to a ‘restricted representation’ in advertising requires a formal application to the TGA’s Delegate of the Secretary.

Two of the 13 medicines were cancelled at the request of the sponsor after receiving a TGA request for information. The sponsors of both medicines stated they had been discontinued and no longer manufactured. The remaining 11 progressed to review.

During the process, one medicine was cancelled before the review was completed. The remaining 10 were assessed and found to be non-compliant.

In total, the TGA stated five of the 10 medicines reviewed referred to the restricted representation of macular degeneration either directly or indirectly, included indications that were not sufficiently supported by the evidence held by the sponsor and advertised indications that were not included on the Australian Register of Therapeutic Goods (ARTG).

As such, one of those was cancelled by the sponsor after they were informed of the issues. The labels and/or websites for the four other medicines were revised by the sponsors to remove restricted representations, any unsupported indications, and any indications made about the medicine that were not included on the ARTG.

The remaining five of the 10 medicines reviewed did not refer to the restricted representation of macular degeneration, but included indications that were not sufficiently supported by the evidence held by the sponsor.

As a result, three of those were cancelled by the sponsor after they were informed of the issues with their medicine. The labels and/or websites for two medicines were revised by the sponsors to remove any unsupported indications relating to eye health.

Advice to suppliers

Following the review, the TGA advised sponsors of listed medicines with indications relating to the eye, and in particular the macula, are encouraged to re-assess their ARTG entry, label and advertising material and ensure their compliance with regulatory obligations.

Its advice to sponsors based on the outcome of the review is:

  1. Ensure appropriate evidence to support all indications for the medicine.
  2. Ensure prior approval from the TGA for reference to restricted representations in the advertising materials.
  3. Remember that unacceptable presentation of a medicine includes; referring to unsupported indications on the labels and any other advertising material; having a name that implies a therapeutic benefit not supported by evidence; having any statements on the label or any advertising material that may mislead consumers to believe the medicine possess characteristics it does not have.

Related Posts

Cyber attackers are often driven by financial gain, with healthcare practices considered a lucrative target. Image: Lee Charlie/Shutterstock.com.

Don’t be blindsided by a cyber attack

by Staff Writer
June 24, 2025

Interruptions to service delivery and reputational damage are consequences of cyber attacks, which means cyber security should be a top...

Optometrist Michael Young’s daughter, a fourth-year optometry student at QUT, undergoing a visual field test on the VF2000 NEO. Image: Michael Young.

Perimetry remastered with VR device from BOC Instruments

by Staff Writer
June 24, 2025

A Californian-made virtual-reality visual field device has been on the wish list of many Australian optometry practice owners thanks to...

The 2025 meeting is taking place in Melbourne 14-17 November. Image: f11photo/stock.adobe.come & Prime Creative Media.

RANZCO has sights on biggest congress yet in 2025

by Staff Writer
June 24, 2025

RANZCO is anticipating its 2025 congress in Melbourne may be one of the largest yet. Since opening registration on 10...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited